|
Cardiovascular Pharmacology
Citations 181-190 of 1154 total displayed.
|
Past content
(since Jan 1999):
|
- Myocardial Protection, Perioperative Management, and Vascular Biology
Low Dose Nesiritide and the Preservation of Renal Function in Patients With Renal Dysfunction Undergoing Cardiopulmonary-Bypass Surgery: A Double-Blind Placebo-Controlled Pilot Study
- Horng H. Chen, Thoralf M. Sundt, David J. Cook, Denise M. Heublein, and John C Burnett, Jr
Circulation 2007;116:I-134-138I-, doi:10.1161/CIRCULATIONAHA.106.697250
[Abstract]
[Full text]
- Correspondence
Letter by Guarracino et al Regarding Article, "Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships"
- Fabio Guarracino, Luigi Tritapepe, and Andrea Morelli
Circulation 2007;116:e346, doi:10.1161/CIRCULATIONAHA.107.706424
[Full text]
- Correspondence
Response to Letter Regarding Article, "Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships"
- Michael M. Givertz, Costa Andreou, Chester H. Conrad, and Wilson S. Colucci
Circulation 2007;116:e347, doi:10.1161/CIRCULATIONAHA.107.715979
[Full text]
- Articles
Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial
- Benjamin M. Scirica, David A. Morrow, Hanoch Hod, Sabina A. Murphy, Luiz Belardinelli, Chester M. Hedgepeth, Peter Molhoek, Freek W.A. Verheugt, Bernard J. Gersh, Carolyn H. McCabe, and Eugene Braunwald
Circulation published September 5, 2007, doi:10.1161/CIRCULATIONAHA.107.724880
[Abstract]
- Genetics
Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients
- Yanfei Ruan, Nian Liu, Raffaella Bloise, Carlo Napolitano, and Silvia G. Priori
Circulation 2007;116:1137-1144; published online before print as doi:10.1161/CIRCULATIONAHA.107.707877
[Abstract]
[Full text]
- Editorials
Drug-Eluting Stents: Dual Antiplatelet Therapy for Every Survivor?
- Anthony A. Bavry and Deepak L. Bhatt
Circulation 2007;116:696-699, doi:10.1161/CIRCULATIONAHA.107.719484
[Full text]
- Heart Failure
Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes
- Gunnar H. Gislason, Jeppe N. Rasmussen, Steen Z. Abildstrom, Tina Ken Schramm, Morten Lock Hansen, Pernille Buch, Rikke Sørensen, Fredrik Folke, Niels Gadsbøll, Søren Rasmussen, Lars Køber, Mette Madsen, and Christian Torp-Pedersen
Circulation 2007;116:737-744; published online before print as doi:10.1161/CIRCULATIONAHA.106.669101
[Abstract]
[Full text]
- Articles
Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients
- Yanfei Ruan, Nian Liu, Raffaella Bloise, Carlo Napolitano, and Silvia G. Priori
Circulation published August 13, 2007, doi:10.1161/CIRCULATIONAHA.107.707877
[Abstract]
- Corrections
Correction
-
Circulation 2007;116:e135, doi:10.1161/CIRCULATIONAHA.107.186037
[Full text]
- Coronary Artery Disease
Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival
- Nicholas J. Leeper, Reza Ardehali, Emil M. deGoma, and Paul A. Heidenreich
Circulation 2007;116:613-618; published online before print as doi:10.1161/CIRCULATIONAHA.107.694117
[Abstract]
[Full text]
|
|
